Skip to content

Trevi Therapeutics, Inc. TRVI Total Operating Expenses

Total Operating Expenses at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
$139M-10.9%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s total operating expenses?
Trevi Therapeutics, Inc. (TRVI) reported total operating expenses of $14.91M in Q1 2026.
How has Trevi Therapeutics, Inc.'s total operating expenses changed year-over-year?
Trevi Therapeutics, Inc.'s total operating expenses increased by 30.0% year-over-year, from $11.47M to $14.91M.
What is the long-term trend for Trevi Therapeutics, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s total operating expenses has grown at a 11.0% compound annual growth rate (CAGR), from $32.48M to $49.33M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.